In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Existing investors put $26mm more into Sutro Biopharma through Series D round

Executive Summary

Sutro Biopharma Inc. (antibody-drug conjugates and bispecific antibodies for cancer) raised $26mm through a Series D round from returning investors Alta Partners, Amgen Ventures, Celgene Corp. (partner under a 2012 deal), Lilly Ventures, Skyline Ventures, and SV Life Sciences. Proceeds will help expand the company's immuno-oncology pipeline.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Synthesis Technologies, Production Processes
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies